JP2012509886A - 転写制御因子としてのＴｃｌ１ - Google Patents

転写制御因子としてのＴｃｌ１ Download PDF

Info

Publication number
JP2012509886A
JP2012509886A JP2011537606A JP2011537606A JP2012509886A JP 2012509886 A JP2012509886 A JP 2012509886A JP 2011537606 A JP2011537606 A JP 2011537606A JP 2011537606 A JP2011537606 A JP 2011537606A JP 2012509886 A JP2012509886 A JP 2012509886A
Authority
JP
Japan
Prior art keywords
tcl1
cell
activator protein
related disease
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011537606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509886A5 (cg-RX-API-DMAC10.html
Inventor
クロース，カーロ・エム
ペカースキー，ユーリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Publication of JP2012509886A publication Critical patent/JP2012509886A/ja
Publication of JP2012509886A5 publication Critical patent/JP2012509886A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2011537606A 2008-11-21 2009-11-19 転写制御因子としてのＴｃｌ１ Pending JP2012509886A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11678608P 2008-11-21 2008-11-21
US61/116,786 2008-11-21
PCT/US2009/065072 WO2010059779A1 (en) 2008-11-21 2009-11-19 Tcl1 AS A TRANSCRIPTIONAL REGULATOR

Publications (2)

Publication Number Publication Date
JP2012509886A true JP2012509886A (ja) 2012-04-26
JP2012509886A5 JP2012509886A5 (cg-RX-API-DMAC10.html) 2012-06-07

Family

ID=42198493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011537606A Pending JP2012509886A (ja) 2008-11-21 2009-11-19 転写制御因子としてのＴｃｌ１

Country Status (7)

Country Link
US (1) US20110311555A1 (cg-RX-API-DMAC10.html)
EP (1) EP2352524A1 (cg-RX-API-DMAC10.html)
JP (1) JP2012509886A (cg-RX-API-DMAC10.html)
CN (1) CN102271706A (cg-RX-API-DMAC10.html)
AU (1) AU2009316584A1 (cg-RX-API-DMAC10.html)
CA (1) CA2744326A1 (cg-RX-API-DMAC10.html)
WO (1) WO2010059779A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016548A2 (en) 2005-08-01 2007-02-08 The Ohio State University Research Foundation Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
US8481505B2 (en) 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
WO2007081680A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
AU2007205234B2 (en) 2006-01-05 2012-07-12 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
EP2484782B1 (en) 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
ES2446362T3 (es) 2006-03-20 2014-03-07 The Ohio State University Research Foundation Huellas de microARN durante megacariocipoyesis humana
ES2425387T3 (es) 2006-07-13 2013-10-15 The Ohio State University Research Foundation Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
WO2008054828A2 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
JP2010516291A (ja) 2007-01-31 2010-05-20 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 急性骨髄性白血病（ａｍｌ）の診断、予後及び治療のためのマイクロｒｎａに基づく方法及び組成物
US8465917B2 (en) 2007-06-08 2013-06-18 The Ohio State University Research Foundation Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
EP2173911B1 (en) 2007-07-31 2014-06-18 The Ohio State University Research Foundation Methods for reverting methylation by targeting dnmt3a and dnmt3b
EP2653561B1 (en) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
EP3028708A1 (en) 2007-08-22 2016-06-08 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
WO2009055773A2 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
WO2009152300A1 (en) 2008-06-11 2009-12-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found MATERIALS AND METHODS FOR INFLUENCING GROWTH, MIGRATION AND INVASION OF TUMOR CELLS
WO2012065049A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
JP2014509852A (ja) 2011-03-07 2014-04-24 ジ・オハイオ・ステート・ユニバーシティ マイクロＲＮＡ−１５５（ｍｉＲ−１５５）により誘導される変異誘発活性は炎症および癌を結び付ける
CA2852066A1 (en) 2011-10-14 2013-04-18 The Ohio State University Methods and materials related to ovarian cancer
EP2790735A4 (en) 2011-12-13 2015-12-09 Ohio State Innovation Foundation METHODS AND COMPOSITIONS RELATING TO MIR-21 AND MIR-29A, EXOSOME INHIBITION, AND CANCER METASTASIS
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985598A (en) * 1994-10-27 1999-11-16 Thomas Jefferson University TCL-1 gene and protein and related methods and compositions
US20010026796A1 (en) * 2000-03-14 2001-10-04 Croce Carlo M. TCL1 enhances Akt kinase activity and mediates its nuclear translocation
GB0128898D0 (en) * 2001-12-03 2002-01-23 Biotech Res Ventures Pte Ltd Materials and methods relating to the stabilization and activation of a tumour suppressor protein
CA2478065C (en) * 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals

Also Published As

Publication number Publication date
CA2744326A1 (en) 2010-05-27
CN102271706A (zh) 2011-12-07
WO2010059779A1 (en) 2010-05-27
AU2009316584A1 (en) 2010-05-27
US20110311555A1 (en) 2011-12-22
EP2352524A1 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
US20110311555A1 (en) Tc11 as a Transcriptional Regulator
Yang et al. Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation
Song et al. TEA domain transcription factor 1 (TEAD1) induces cardiac fibroblasts cells remodeling through BRD4/Wnt4 pathway
Kundranda et al. The serum glycoprotein fetuin-A promotes Lewis lung carcinoma tumorigenesis via adhesive-dependent and adhesive-independent mechanisms
JP6797027B2 (ja) メタドヘリン−ｓｎｄ１相互作用を遮断するペプチドの癌の治療としての使用
Zhao et al. The regulatory network of CREB3L1 and its roles in physiological and pathological conditions
Meng et al. Imbalanced Rab3D versus Rab27 increases cathepsin S secretion from lacrimal acini in a mouse model of Sjögren's Syndrome
Cui et al. PDGFA‐associated protein 1 is a novel target of c‐Myc and contributes to colorectal cancer initiation and progression
JP2002540814A (ja) 転移性前立腺腫瘍の診断および処置のための方法
Liu et al. Adenosine metabolic clearance maintains liver homeostasis by licensing arginine methylation of RIPK1
JP6442403B2 (ja) 代謝調節のための方法および組成物
Laragione et al. KIF1C and new Huntingtin-interacting protein 1 binding proteins regulate rheumatoid arthritis fibroblast-like synoviocytes’ phenotypes
US9295686B2 (en) Treatment of cancers with A-8R peptide
CA2568201C (en) Identification of ergothioneine transporter and therapeutic uses thereof
Zhang et al. QRICH1 regulates ATF6 transcription to affect pathological cardiac hypertrophy progression
Park et al. YAP1 and TAZ activates mTORC1 pathway by regulating amino acid transporters in hepatocellular carcinoma
TW200831898A (en) Treatment of insulin resistance
WO2016179222A1 (en) Znf532 for diagnosis and treatment of cancer
Fan et al. High-fat diet promotes colorectal carcinogenesis through SERCA2 mediated serine phosphorylation of Annexin A2
US20020160002A1 (en) Tumor suppressor gene
EP4168123B1 (en) Biomarker based patient selection for proteasome inhibitor treatment
WO2011150516A1 (en) Diagnostic, screening and therapeutic applications of ocab-based tools
US20160287575A1 (en) Compositions and methods for the treatment of diseases involving hippo pathway
Zhang et al. Phosphorylation dependent mitochondrial translocation of Nr4a3 provokes cardiomyocyte death
Wang et al. Lysine methylation promotes NFAT5 activation upon EGFR activation and predicts the efficacy of temozolomide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120329

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20130731